Literature DB >> 21383543

DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer.

Zhen Wang1, Zhaoli Chen, Yushun Gao, Ning Li, Baozhong Li, Fengwei Tan, Xiaogang Tan, Ning Lu, Yuntian Sun, Jian Sun, Nan Sun, Jie He.   

Abstract

Lung cancer is the leading cause of cancer-related death in the world and approximately 30-40% of patients with stage Ⅰ non-small cell lung cancer (NSCLC) die of recurrent disease. miRNA expression profiles can be diagnostic and prognostic markers of lung cancer. Recently, miR-34 family has been shown to be part of the p53 pathway which is frequently involved in lung cancer, and the expression of miR-34 has been reported to be regulated by DNA methylation. In present study, we investigated the correlation between DNA methylation status of miR-34 family and recurrence of stage Ⅰ NSCLC patients. miR-34a and miR-34b/c promoter methylation status were determined by nested methylation-specific PCR in FFPE tumor tissues from 161 patients of stage Ⅰ NSCLC. Furthermore, mature miR-34b and miR-34c expression were analyzed by qRT-PCR in the same panel tissues. Our results revealed that aberrant DNA methylation of miR-34b/c was correlated with a high probability of recurrence (p = 0.026) and associated with poor overall survival (p = 0.010) and disease-free survival (p = 0.017). No significant association was found for miR-34a methylation. Multivariate analysis showed that promoter hypermethylation of miR-34b/c was an independent prognostic factor of stage Ⅰ NSCLC. Moreover, no significant association between mature miR-34b and miR-34c expression and DNA methylation status was found. In conclusion, we have identified promoter hypermethylation of miR-34b/c as a relatively common event in NSCLC and might be a potential prognostic factor for stage Ⅰ NSCLC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383543     DOI: 10.4161/cbt.11.5.14550

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  54 in total

Review 1.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

Review 2.  Human RNAi pathway: crosstalk with organelles and cells.

Authors:  Sadegh Azimzadeh Jamalkandi; Esmaeel Azadian; Ali Masoudi-Nejad
Journal:  Funct Integr Genomics       Date:  2013-11-07       Impact factor: 3.410

3.  Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases.

Authors:  Laura E Stevens; William K C Cheung; Sally J Adua; Anna Arnal-Estapé; Minghui Zhao; Zongzhi Liu; Kelly Brewer; Roy S Herbst; Don X Nguyen
Journal:  Cancer Res       Date:  2017-02-14       Impact factor: 12.701

Review 4.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

5.  Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes.

Authors:  Hyang Sook Seol; Yoshimitsu Akiyama; Shu Shimada; Hee Jin Lee; Tae Im Kim; Sung Min Chun; Shree Ram Singh; Se Jin Jang
Journal:  Cancer Lett       Date:  2014-07-22       Impact factor: 8.679

6.  MicroRNAs As Biomarkers For Clinical Features Of Lung Cancer.

Authors:  Roland Hubaux; Daiana D Becker-Santos; Katey S S Enfield; Stephen Lam; Wan L Lam; Victor D Martinez
Journal:  Metabolomics (Los Angel)       Date:  2012-03-21

7.  Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer.

Authors:  Xuan-di Wu; Yong-Chun Song; Pei-Long Cao; Hao Zhang; Qi Guo; Rong Yan; Dong-Mei Diao; Yao Cheng; Cheng-Xue Dang
Journal:  Med Oncol       Date:  2014-02-27       Impact factor: 3.064

Review 8.  MicroRNA as tools and therapeutics in lung cancer.

Authors:  Jennifer F Barger; S Patrick Nana-Sinkam
Journal:  Respir Med       Date:  2015-02-19       Impact factor: 3.415

Review 9.  DNA methylation and microRNA dysregulation in cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Masahiro Kai
Journal:  Mol Oncol       Date:  2012-08-10       Impact factor: 6.603

Review 10.  The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.

Authors:  Brian D Adams; Christine Parsons; Frank J Slack
Journal:  Expert Opin Ther Targets       Date:  2015-12-11       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.